Clinical trials: Vulvar Disease
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
- Trial name
- NCT05952947
- Testing
- HRYZ-T101 Injection, Fludarabine + Cyclophosphamide
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HRYZ Biotech Co.
Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
The study is a single arm, retrospective, single-center, post market registry. The purpose of this Registry is to collect data to demonstrate the safety and performance of CUSA® for the treatment of Vulvar Intraepithelial…
- Trial name
- NCT06297187
- Testing
- CUSA (Cavitronic Ultrasonic Surgical Aspirator)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Integra LifeSciences Corporation
Bladder Cancer, Squamous Cell Carcinoma of the Lung
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have…
- Conditions
- Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
- Trial name
- NCT07217171
- Testing
- EVOLVE104
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- EvolveImmune United, Inc
Human Papilloma Virus Infection
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
This trail is to evaluate the safety profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy Chinese women ages 20-45 and determine the optimal ratio of…
- Trial name
- NCT05694728
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
- Where
- China
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Atrophy, Vaginal Diseases
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg…
- Trial name
- NCT00630539
- Testing
- Ospemifene 5 mg, Ospemifene 15 mg, Ospemifene 30 mg
- Volunteers
- 126 people
- Sponsor
- Shionogi
Vaginal Atrophy
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.
- Trial name
- NCT01358760
- Testing
- DHEA
- Where
- 42 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- EndoCeutics Inc.
Atrophic Vaginitis, Vaginal Atrophy
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term…
- Conditions
- Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
- Trial name
- VALOR (NCT05953090)
- Testing
- 7-0940
- Where
- 14 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Stratpharma AG
Lichen Sclerosus
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants With Lichen Sclerosus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 12 weeks…
- Trial name
- NCT05593445
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 14 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Vulvovaginal Candidiases, Yeast Infection
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal
- Trial name
- NCT03167957
- Testing
- Oral Encochleated Amphotericin B (CAMB)
- Where
- United States
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Vaginal Atrophy
DHEA Against Vaginal Atrophy - 3-Month Efficacy Study
The purpose of this Phase III trial is to confirm the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.
- Trial name
- NCT01256684
- Testing
- DHEA
- Where
- 33 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- EndoCeutics Inc.
Sarcoma, Melanoma
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
The purpose of this study is to evaluate the safety and tolerability of different doses and administration regimens of Stimotimagene copolymerplasmid in patients with histologically confirmed diagnosis of solid tumor and/or its…
- Conditions
- Sarcoma, Melanoma, Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms
- Trial name
- NCT05578820
- Testing
- Stimotimagene copolymerplasmid, Ganciclovir
- Where
- 4 sites in Russia
- Volunteers
- 21 people
- Sponsor
- Gene Surgery LLC
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- NCT03734991
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 376 people
- Sponsor
- Scynexis, Inc.
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Vulvovaginal Candidiasis
Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms
Women diagnosed with Vulvovaginal Candidiasis by the health care professional will be enrolled in the study. All participants should fulfil inclusion and exclusion criteria. The study product will be used for 5 days, once a day.
- Trial name
- NCT05552378
- Testing
- Multi-Gyn FloraFem
- Where
- Poland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Karo Pharma AB
Vulvovaginal Candidiasis
The Study Of Fluconazole For Vulvovaginal Candidiasis
As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas.
- Trial name
- NCT01806623
- Testing
- Fluconazole
- Where
- 10 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Pfizer
Atrophy, Vaginal Diseases
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
The purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.
- Trial name
- NCT00729469
- Testing
- Ospemifene 60 mg
- Volunteers
- 919 people
- Sponsor
- Shionogi
HPV-induced Cancers
Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers
The study will include 10 patients with HPV-associated ano-genital cancer (cervical, vulvar, vaginal, penile, anal) or HPV-associated head and neck cancer, who are planned to receive a cisplatin-based chemotherapy (alternatively…
- Trial name
- VICORYX-2 (NCT02526316)
- Testing
- P16_37-63 peptide combined with Montanide® ISA-51 VG, P16_37-63 peptide without Montanide® ISA-51 VG
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Oryx GmbH & Co. KG
Candidiasis, Vulvovaginal, Mycoses
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
The purpose of this study is to determine if two topical formulations of CD101 are safe and effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC) compared to oral fluconazole.
- Conditions
- Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal
- Trial name
- NCT02733432
- Testing
- CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%)
- Where
- 24 sites in United States
- Volunteers
- 126 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- Vanish 306 (NCT03987620)
- Testing
- Ibrexafungerp
- Where
- 41 sites in United States, Bulgaria
- Volunteers
- 455 people
- Sponsor
- Scynexis, Inc.